A study of utilization pattern of drugs in HIV positive patients at antiretroviral therapy centre of a tertiary care teaching hospital
Keywords:Antiretroviral therapy, Drug utilization study, HIV/AIDS
Background: Infection with human immunodeficiency virus (HIV) and subsequent acquired immunodeficiency syndrome (AIDS) continues to be a major public health problem. Treatment and therapeutic guidelines have evolved over a period of time. Drug utilization study helps to evaluate changing pattern of drug use, compliance with national guidelines and rational use of drugs.
Methods: Authors conducted observational, non interventional, descriptive study in outdoor HIV positive patients for one year. We have analysed collected data using descriptive statistics to determine drug use indicators and utilization pattern of drugs.
Results: Study showed that average number of drugs per encounter was 3.96. The most commonly prescribed antiretroviral therapy (ART) regime was combination of zidovudine, lamivudine with nevirapine (51.92%). Among antiretroviral drugs prescribed, nucleoside reverse transcriptase inhibitors (49.45%) were the most common drug subclass and lamivudine (33.33%) was the most common antiretroviral drug. Second most common medication class was antibacterial agents (18.77%) and co-trimoxazole (10.11%) was the most common antibacterial agent. The third most commonly prescribed drug class was vitamins namely folic acid and multivitamins (2.63 %). Percentage of encounters with an antibiotic prescribed was 41.46%. Tuberculosis was the most common opportunistic infection. In 90.05% of encounters with ART prescriptions, adherence was more than 95%.
Conclusions: Overall the results suggest that the prescribing pattern to be in accordance with national guidelines and reflect changing patterns of drug usage in HIV positive patients in World. Drug use indicators reflect rational approach to prescribing pattern.
UNAIDS. UNAIDS factsheet, 2017. Available at: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf. Accessed 01 November 2017.
Flexner C. Antiretroviral agents and treatment of HIV Infection. In: Burton LL, ed. Goodman and Gillman’s The Pharmacological Basis of Therapeutics. 12th Ed. New York, NY: McGraw-Hill; 2011:1623-1664.
National AIDS Control Organization. NACO annual report 2016-17, 2017. Available at: http://naco.gov.in/sites/default/files/NACO%20ANNUAL%20REPORT%202016-17.pdf. Accessed 01 November 2017.
World Health Organization. Introduction to Drug Utilization Research. Geneva: World health organization; 2003.
National AIDS Control Organisation. Antiretroviral Therapy Guidelines for HIV-Infected Adults and Adolescents: May 2013. New Delhi: Ministry of Health and Family Welfare Government of India; 2013.
Jiyo C, Suthar SD, Dholaria NK, Chavda DA, Bhansali NB, Gosai TR, et al. Drug utilization study of HIV positive patients registered with antiretroviral therapy centre of a tertiary care hospital. J Clin Exp Res. 2013;1(1):12-9.
Prakash-Raju GJK, Chowta MN, Rather ZA, Mubeen F. The Pattern of the Initial Anti-retroviral Drug Regimes in HIV Patients at a Tertiary Care Hospital. J Clin Diagn Res. 2012;6(7):1178-80.
Hasabi IS, Shivashankarappa AB, Kachapur C, Kaulgud RS. A Study of Compliance to Antiretroviral Therapy among HIV Infected Patients at a Tertiary Care Hospital in North Karnataka. J Clin Diagn Res. 2016 May;10(5):27-31.
Patrikar S, Subramaniam S, Vasudevan B, Bhatti V, Kotwal A, Basannar D, et al. AIDS & Clinical Profile of HIV Patients on Second Line Antiretroviral Therapy: The Indian Experience. J AIDS Clin Res. 2015;6(5):1-5.
National AIDS Control Organization. Antiretroviral Therapy Guidelines for HIV-Infected Adults and Adolescents Including Post-Exposure Prophylaxis May 2007. New Delhi: Ministry of Health and Family Welfare Government of India; 2007.
Mocroft A, Johnson MA, Philips AN. Factors affecting survival in patients with acquired immune deficiency syndrome. AIDS. 1996;10:1057-65.
Obirikorang C, Selleh PK, Abledu JK, Fofie CO. Predictors of Adherence to Antiretroviral Therapy among HIV/AIDS Patients in the Upper West Region of Ghana. ISRN AIDS. 2013;2013:1-7.
World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach - 2010 rev. Geneva: World Health Organization; 2010.
Duber HC, Dansereau E, Masters SH, Achan J, Burstein R, DeCenso B, et al. Uptake of WHO recommendations for first-line antiretroviral therapy in Kenya, Uganda, and Zambia. PLoS One. 2015;10:1-12.
World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a public health approach. Geneva: World Health Organization; 2006.
Jiménez-Nácher I, García B, Barreiro P, Rodriguez-Novoa S, Morello J, González-Lahoz J, et al. Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. J Antimicrob Chemother. 2008;62:816-22.
Oreagba IA, Usman SO, Akanmu S. Antiretrovirals and Co-Prescribed Drugs for People Living With HIV/AIDS in a University Teaching Hospital, South West Nigeria. Value Heal. 2016;19:A212-3.
Easterbrook P, Phillips A, Hill T, Matthias R, Fisher M, Gazzard B, et al. Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK. HIV Med. 2008;9:47-56.
Ribeiro FA, Tupinambás U, Fonseca MO, Greco DB. Durability of the first combined antiretroviral regime in patients with AIDS at a reference center in Belo Horizonte, Brazil, from 1996 to 2005. Brazilian J Infect Dis. 2012;16(1):27-33.
Sapkota S, Shakya R, Pandey B. Study on Highly Active Anti Retroviral Therapy: prescription pattern and side effects. JNPA. 2012;26(1):12-8.
Ghani AC, Donnelly CA, Anderson RM. Patterns of antiretroviral use in the United States of America: Analysis of three observational databases. HIV Med. 2003;4:24-32.
Fogelman I, Lim L, Bassett R, Volberding P, Fischl MA, Stanley K, et al. Prevalence and Patterns of Use of Concomitant Medications Among Participants in Three Multicenter Human Immunodeficiency Virus Type I Clinical Trials. J Acquir Immune Defic Syndr. 1994 October;7(10):1057-63.
National AIDS Control Organization. Guidelines for Prevention and Management of Common Opportunistic Infections/Malignancies among HIV-Infected Adult and Adolescent. New Delhi: Ministry of Health and Family Welfare Government of India; 2007.
Giri PA, Deshpande JD, Phalke DB. Prevalence of pulmonary tuberculosis among HIV positive patients attending antiretroviral therapy clinic. N Am J Med Sci. 2013;5:367-70.
Trinh QM, Nguyen HL, Nguyen VN, Nguyen TVA, Sintchenko V, Marais BJ. Tuberculosis and HIV co-infection-focus on the Asia-Pacific region. Int J Infect Dis. 2015;32:170-8.
Sarna A, Pujari S, Sengar AK, Garg R, Gupta I, Dam J. Adherence to antiretroviral therapy & its determinants amongst HIV patients in India. Indian J Med Res. 2008;127:28-36.
Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS. 2007 May;21(8):965-71.
Marchand C, Himmich H, Maaroufi A, Sohier N, Chambon JF, Gagnayre R. Implementation and assessment of an HIV treatment training program (2000-2001) for patients in Casablanca (Morocco), Sante. 2005;15:73-80.
Tatkare SN, Tatkare N, Giri K, Totade S. Analysis of Prescribing Trends at Tertiary Care Teaching Hospital of central India. European Journal of Pharmaceutical and Medical Research. 2016;3(3):463-9.
World Health Organization. The World Medicines Situation. Geneva: World Health Organization; 2004.
Clay PG. Actual medication pill burden and dosing frequency in HIV-infected patients with undetectable viral loads. J Int Assoc Physicians in AIDS Care (Chic). 2004;3(2):49-55.
Ministry of Health and Family Welfare Government of India. National List of Essential Medicines, 2015 Available at: http://cdsco.nic.in/WriteReadData/NLEM-2015/NLEM,%202015.pdf. Accessed 20 October 2016.
World health organization. WHO Policy Perspectives on Medicines- Continuity and Change-Implementing the third WHO Medicines Strategy 2008-2013. Geneva: World health organization; 2010.